Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAST-TIL
- Development stage
- Unknown
- Lead developer
- Huasai Biomedicine
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
**FAST-TIL** (also known as **HS-IT101**) is an autologous, non-genetically modified tumor-infiltrating lymphocyte (TIL) cell therapy developed by Huasai Biomedicine (formerly Sino-cell Biomedicine) for the treatment of advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Manufactured using the proprietary PowerTexp® platform, FAST-TIL requires a minimal starting tumor tissue sample (less than 0.05 g) and features a shortened 14-day production cycle. The therapy is designed to recognize and attack patient-specific tumor neoantigens with reduced dependence on high-dose interleukin-2 (IL-2) and intensive lymphodepletion, thereby improving safety and clinical accessibility. FAST-TIL is currently in Phase II clinical development for advanced melanoma and Phase I/Ib development for NSCLC and RCC.
- Other names
- EAST-TILFAST-TIL
Beyond the preview
Go deeper on FAST-TIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAST-TIL.